Workflow
其他风险警示
icon
Search documents
ST东时:撤销部分其他风险警示,继续被实施其他风险警示
Xin Lang Cai Jing· 2025-08-22 13:14
ST东时8月22日公告,公司此前因被控股股东东方时尚投资及其关联人非经营性占用资金,余额达到最 近一期经审计净资产绝对值5%以上,且金额超过1000万元,未能在1个月内完成清偿或整改被叠加实施 其他风险警示。现上述其他风险警示情形已完全消除,公司已向上海证券交易所申请撤销对公司股票实 施的相应其他风险警示情形。目前,上述申请已经获得上海证券交易所审核批准。截至本公告披露日, 关于公司前期被实施其他风险警示的情形尚未全部消除。本次公司股票被撤销部分其他风险警示,但仍 存在其他被实施风险警示的情形。公司股票简称、股票交易的日涨跌幅限制不会发生变化。 ...
ST景谷: 股票交易风险提示公告
Zheng Quan Zhi Xing· 2025-08-21 16:35
Core Viewpoint - The company is facing significant operational and financial challenges due to legal issues affecting its major subsidiary, which has halted production and may lead to substantial revenue declines [1][2][3] Market Trading Risks - The company's stock price has experienced significant volatility, with a cumulative price increase exceeding 12% over three consecutive trading days, triggering abnormal fluctuation standards [1] - The stock reached its daily limit up on multiple occasions, indicating potential short-term risks of price correction [1] Major Asset Restructuring Risks - The company is in the preliminary stages of planning a major asset sale, which could drastically reduce its main business scale, as the subsidiary's revenue accounted for 87.02% of the company's audited revenue for the previous year [2] - The asset sale is still under discussion and has not yet resulted in a formal agreement, leading to significant uncertainty regarding the transaction [2] Legal and Financial Risks - The subsidiary is involved in 12 legal cases with a total claim amount of approximately 95.15 million yuan, which poses a risk to the company's net assets [2][3] - The subsidiary's production lines are currently shut down due to court-ordered asset preservation measures, leading to a halt in normal operations and a significant drop in sales revenue [3] Inventory Loss Risks - The subsidiary reported an inventory loss of approximately 19 million yuan due to unauthorized sales by a board member, which may result in a loss of about 9.69 million yuan attributable to the parent company [3] - The ongoing investigation by law enforcement may further complicate the recovery of lost assets [3] Financial Performance Risks - The company anticipates a substantial decline in its half-year financial performance, projecting a net loss of between 130 million yuan and 100.3 million yuan [3] - The company has faced negative net profits for three consecutive years, raising concerns about its ability to continue as a going concern [4]
云南景谷林业股份有限公司 股票交易风险提示公告
Group 1 - The company's stock price experienced significant fluctuations, with a cumulative increase of over 12% in three consecutive trading days from August 13 to August 15, 2025, triggering abnormal trading standards as per the Shanghai Stock Exchange regulations [1] - On August 18, 2025, the company's stock closed at the daily limit price again, indicating continued volatility in the stock price [1] Group 2 - The company plans to sell a 51% stake in Tangxian Huiyin Wood Industry Co., Ltd. to its controlling shareholder, Zhou Dafu Investment Co., Ltd., or its designated affiliates, which is still in the planning stage and subject to further discussions and necessary approvals [2] - The sale of Huiyin Wood, which accounted for 87.02% of the company's audited revenue in 2024, may lead to a significant decline in the company's main business scale and could trigger delisting risk warnings if revenue falls below 300 million yuan and net profit is negative [2] Group 3 - The company's subsidiary, Huiyin Wood, is involved in 12 legal cases with a total amount of approximately 95.15 million yuan, which represents 100.05% of the company's latest audited net assets attributable to shareholders [3] - The main production assets of Huiyin Wood have been subjected to property preservation measures by the courts, leading to the suspension of its two production lines for fiberboard and particleboard, with no estimated time for resumption of operations [3] Group 4 - Huiyin Wood reported a loss of approximately 19 million yuan in inventory due to mismanagement by a former controlling shareholder, which may result in a loss of about 9.69 million yuan attributable to the listed company [4] - The company has initiated legal proceedings against the former shareholder for the recovery of the lost inventory and funds [4] Group 5 - The company anticipates a significant decline in its half-year performance for 2025, projecting a net loss attributable to shareholders of between 130 million yuan and 105 million yuan, with a net loss excluding non-recurring gains and losses between 100.3 million yuan and 68.7 million yuan [5] Group 6 - The company has been under other risk warnings since April 30, 2025, due to negative net profits for three consecutive fiscal years, raising concerns about its ability to continue as a going concern [6]
江西沐邦高科股份有限公司关于控股股东股权司法冻结的公告
Core Viewpoint - Jiangxi Mubang High-Tech Co., Ltd. (hereinafter referred to as "the company") announced that its controlling shareholder, Jiangxi Mubang New Energy Holdings Co., Ltd. (hereinafter referred to as "Mubang New Energy Holdings"), has had all of its shares frozen due to judicial actions, which may impact the company's financial stability and operations [2][3][6]. Group 1: Shareholder's Shareholding and Freezing Situation - Mubang New Energy Holdings holds 87,540,610 shares, accounting for 20.19% of the company's total share capital. As of the announcement date, 83,300,000 shares (95.16% of its holdings) are under judicial freeze, representing 19.21% of the company's total share capital [2]. - The frozen shares include 4,240,610 shares under multiple rounds of freezing, which accounts for 0.98% of the company's total share capital [2]. - The freezing is due to two court cases with debt amounts of 150,345,405.00 yuan and 169,197,323.84 yuan, respectively, involving a total of 86,000,000 shares [3]. Group 2: Stock Trading Anomalies - The company's A-share stock experienced a cumulative price deviation of over 12% across three consecutive trading days, which is classified as an abnormal trading fluctuation according to the Shanghai Stock Exchange rules [6][8]. - The company conducted a self-examination and confirmed that there are no undisclosed significant matters affecting the stock price, aside from previously disclosed information [9][10]. Group 3: Financial and Legal Issues - The company received a notice from the China Securities Regulatory Commission (CSRC) regarding an investigation into potential false disclosures in its annual reports [6][13]. - As of June 30, 2025, the controlling shareholder had non-operating fund occupation balances of 46.0563 million yuan, which exceeds 5% of the company's latest audited net assets [7][14]. - The company has faced judicial deductions totaling 227.5921 million yuan from its fundraising accounts, which may affect the implementation of its fundraising projects [7][14].
江西沐邦高科股份有限公司 股票交易异常波动公告
Core Viewpoint - Jiangxi Mubang High-tech Co., Ltd. has experienced abnormal stock price fluctuations, with a cumulative deviation of over 12% in closing prices over three consecutive trading days, prompting regulatory scrutiny [2][5]. Group 1: Stock Trading Abnormalities - The company's stock price showed a cumulative deviation of over 12% on July 30, 31, and August 1, 2025, indicating abnormal trading activity [5]. - The company conducted a self-examination and confirmed that there were no undisclosed significant matters affecting the stock price, including major asset restructuring or significant transactions [8][10]. Group 2: Financial and Operational Status - The company reported that its production and operational activities are normal, with no significant changes in market conditions or internal operations [7]. - The company disclosed a negative net profit for the fiscal year 2024, leading to a risk warning for its stock on May 6, 2025, due to revenues falling below 300 million yuan after excluding non-core business income [2]. Group 3: Legal and Regulatory Issues - The company has faced legal challenges, with a total of 227.59 million yuan in judicial deductions from its fundraising accounts, impacting project implementations [3][11]. - The company received a corrective order from the China Securities Regulatory Commission (CSRC) regarding non-operating fund occupation by its controlling shareholder, amounting to 46.06 million yuan [3][12]. - The CSRC has initiated an investigation into the company for suspected false disclosures in its annual reports and other periodic reports [3][13].
江苏华盛天龙光电设备股份有限公司 关于公司股票交易其他风险警示的进展公告
Core Viewpoint - The company is facing significant operational challenges, including frozen bank accounts and potential changes in control due to legal disputes involving its major shareholder [2][3][16]. Group 1: Legal and Financial Issues - Deyou Holdings Limited is involved in an arbitration case with Ms. Chen Hua, resulting in a court ruling that may lead to the auction of 14,000,000 shares, representing 54.69% of Deyou Holdings' total shares and 6.98% of the company's total equity [2][16]. - The company disclosed that its wholly-owned subsidiary, Sichuan Zhongshu Shilian Construction Engineering Co., Ltd., had its main bank accounts frozen due to a contractual dispute, affecting 99.49% of its cash balance [3][10]. - The company has been under continuous risk warnings due to negative net profits over the last three fiscal years, with the latest audited net profit for 2024 reported at -27,303,694.80 yuan [4][9][17]. Group 2: Operational Performance - The company has struggled with production and operational activities since December 2018, leading to a significant decline in market orders and ongoing production halts [5][11]. - In 2023, the company achieved a revenue of 368,402,027.39 yuan but reported a net loss of -8,582,265.60 yuan, indicating ongoing financial difficulties [12][13]. - The company is attempting to pivot towards renewable energy projects, with signed contracts in 2024 totaling 38,511,168.67 yuan for EPC engineering and 42,251,262.72 yuan for equipment sales, although the overall business scale has decreased [13].
*ST沐邦: 江西沐邦高科股份有限公司股票异常波动
Zheng Quan Zhi Xing· 2025-08-01 16:35
Core Viewpoint - Jiangxi Mubang High-tech Co., Ltd. has experienced abnormal stock trading fluctuations, with a cumulative closing price deviation of 12% over three consecutive trading days, leading to regulatory scrutiny and potential delisting risks [1][3]. Group 1: Stock Trading Fluctuations - The company's A-share stock has seen a cumulative closing price deviation of 12% over three consecutive trading days, qualifying as abnormal trading activity according to Shanghai Stock Exchange regulations [1]. - The company has conducted a self-examination and confirmed that there are no undisclosed significant information affecting the stock price, aside from what has already been disclosed [1][5]. Group 2: Financial Performance and Risks - The 2024 annual report revealed a negative net profit, with operating revenue below 300 million yuan after excluding non-core business income, resulting in a delisting risk warning effective May 6, 2025 [1][2]. - The company has received a negative opinion in its internal control audit report for 2024, leading to additional risk warnings [2]. - Legal issues have led to the freezing of bank accounts totaling approximately 27.75 million yuan, including 26.86 million yuan from the fundraising account, which may impact project implementation [2][3]. Group 3: Regulatory Actions - The company has been notified of an investigation by the China Securities Regulatory Commission (CSRC) due to suspected false disclosures in financial reports [3][7]. - As of June 2025, non-operating fund occupation by the controlling shareholder and related parties reached 81.32 million yuan, exceeding 5% of the company's latest audited net assets, which may lead to further regulatory actions if not resolved within one month [2][6]. Group 4: Corporate Governance - The board of directors has confirmed that there are no undisclosed matters that should have been reported according to the Shanghai Stock Exchange regulations, and previous disclosures do not require correction or supplementation [8].
通化葡萄酒股份有限公司关于股票被实施其他风险警示相关事项的进展公告
登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码:600365 证券简称:ST通葡 公告编号:临2025-038 通化葡萄酒股份有限公司 关于股票被实施其他风险警示相关事项的进展公告 2021年4月30日,公司披露了《ST通葡关于违规担保自查公告》(公告编号:临2021-044),公司披露 了截至2021年4月29日相关公司违规担保的解决进展及影响。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容 的真实性、准确性和完整性承担法律责任。 2021年8月31日,公司披露了《通化葡萄酒股份有限公司关于违规担保事项解除进展公告》(公告编 号:临2021-077),公司对相关公司的相关担保、还款等责任已经解除。 重要内容提示: ● 通化葡萄酒股份有限公司(以下简称"公司")因触及《上海证券交易所股票上市规则》(2019年4月 修订)13.4.1第(五)项规定,公司股票被实施 "其他风险警示"。 ● 根据《上海证券交易所股票上市规则》(2025年4月修订)第9.8.4条规定,公司将每月披露一次其他 风险警示相关事项的进展情况,提示相关风险。 一、公司被实施其他风险警 ...
*ST信通:撤销退市风险警示,继续被实施其他风险警示
news flash· 2025-07-07 10:19
*ST信通(600289)公告,公司撤销退市风险警示和部分其他风险警示,并于2025年7月9日起复牌。公 司2024年实现营业收入3.2亿元,归属于母公司所有者的净利润为-9670.78万元,扣除非经常性损益后的 净利润为-5447.57万元,归属于上市公司股东的净资产为6.26亿元。公司剩余需承担赔偿责任的违规担 保案件涉案本金合计为6.06亿元。公司股票简称变更为"ST信通",股票代码"600289"保持不变,股票交 易价格的日涨跌幅限制仍为5%。 ...
突发利空!002581,将被ST
中国基金报· 2025-07-05 05:07
Core Viewpoint - Unimed Pharmaceutical is facing significant operational challenges due to the suspension of its core subsidiary, Tianjin Unimed Biopharmaceutical Co., Ltd, which is expected to impact 60% of the company's revenue [5][6][12]. Group 1: Company Operations - Tianjin Unimed has been suspended from production and sales since April 22, 2024, due to non-compliance with drug production quality management standards [6][9]. - The expected recovery timeline for Tianjin Unimed's operations has been extended, with a new estimate indicating that normal production will not resume until July 21, 2025 [8]. - The suspension has triggered a chain reaction in the procurement market, with several regions halting purchases of interferon products produced by Tianjin Unimed [9]. Group 2: Financial Impact - In 2024, Tianjin Unimed generated revenue of 217 million yuan, accounting for 60.09% of Unimed Pharmaceutical's total revenue and 9.8% of its consolidated net profit [6]. - Unimed Pharmaceutical has reported continuous losses over the past three years, with net profits of -14.68 million yuan in 2022, -332 million yuan in 2023, and -137 million yuan in 2024 [12]. - The company's first-quarter performance in 2024 showed a revenue decline of 57.84% year-on-year, with a net profit of -36.85 million yuan, down 33.01% [12]. Group 3: Regulatory and Compliance Issues - Unimed Pharmaceutical has faced long-standing internal control risks, including failure to disclose related party transactions and inaccurate earnings forecasts [11]. - The company has been penalized by the China Securities Regulatory Commission for various compliance failures, resulting in fines and a 10-year market ban for its former chairman [11].